Skip to main content

Drug Interactions between Allegra and st. john's wort

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

fexofenadine St. John's wort

Applies to: Allegra (fexofenadine) and st. john's wort

Acute administration of St. John's wort may increase the bioavailability of fexofenadine, while chronic administration reverses the effects and may actually reduce the bioavailability of fexofenadine. St. John's wort appears to initially inhibit and then gradually induce intestinal P-glycoprotein following multiple doses, resulting in altered secretion and absorption of fexofenadine. Alternatively, large single doses may inhibit P-glycoprotein, whereas smaller, multiple daily doses tend to induce P-glycoprotein. In 12 healthy volunteers, coadministration of a single 900 mg dose of St. John's wort significantly increased the peak plasma concentration (Cmax) of fexofenadine (60 mg single oral dose) by 45% and decreased its oral clearance by 20% compared to fexofenadine administered alone. In contrast, after two weeks of treatment with St. John's wort 300 mg three times a day, fexofenadine Cmax and systemic exposure were consistently decreased and oral clearance increased relative to pretreatment. Although not statistically significant, the changes were substantial in some individuals. Compared to single-dose administration of St. John's wort, long-term treatment resulted in a 35% decrease in Cmax and 47% increase in oral clearance of fexofenadine. In another study, St. John's wort at the same dosage given for 12 days significantly decreased the Cmax of a single 180 mg dose of fexofenadine by 39% and increased its oral clearance by 94% in 21 healthy subjects. The clinical significance of these pharmacokinetic changes is unknown.

References

  1. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD (2002) "Effect of St John's wort on the pharmacokinetics of fexofenadine." Clin Pharmacol Ther, 71, p. 414-20
  2. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB (2003) "Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects." Clin Pharmacol Ther, 73, p. 41-50

Switch to consumer interaction data

Drug and food interactions

Moderate

fexofenadine food

Applies to: Allegra (fexofenadine)

GENERALLY AVOID: Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine. The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate. In a five-way crossover study with 10 healthy volunteers, 1/4-strength grapefruit juice, grapefruit juice, orange juice and apple juice (300 mL with drug administration and 150 mL every 1/2 hour for up to 3 hours, total volume 1.2 L) reduced the mean area under the plasma concentration-time curve (AUC) of a 120 mg dose of fexofenadine by 23%, 67%, 72% and 77%, respectively, compared to water. Mean peak plasma concentration (Cmax) was similarly affected. The clinical significance of these changes is unknown. However, results from studies using histamine-induced skin wheals and flares found that the size of wheal and flare was significantly larger when fexofenadine was administered with either grapefruit or orange juices compared to water.

MANAGEMENT: To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water. In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.

References

  1. Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB (2001) "Reduction of fexofenadine bioavailability by fruit juices." Clin Pharmacol Ther, 69, PI-82
  2. Dresser GK, Bailey DG, Leake BF, et al. (2002) "Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine." Clin Pharmacol Ther, 71, p. 11-20

Switch to consumer interaction data

Moderate

St. John's wort food

Applies to: st. john's wort

GENERALLY AVOID: An isolated case report suggests that foods containing large amounts of tyramine may precipitate a hypertensive crisis in patients treated with St. John's wort. The mechanism of interaction is unknown, as St. John's wort is not thought to possess monoamine oxidase (MAO) inhibiting activity at concentrations achieved in vivo. The case patient was a 41-year-old man who had been taking St. John's wort for seven days prior to presentation at the emergency room with confusion and disorientation. The patient recalled last eating aged cheese and having a glass of red wine approximately 10 hours prior to admission. No other cause of delirium or hypertension could be identified. In addition, alcohol may potentiate some of the pharmacologic effects of St. John's wort. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Until further information is available, patients treated with St. John's wort should consider avoiding consumption of protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, yogurt, papaya products, meat tenderizers, fava beans, protein extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. Patients should also be advised to avoid or limit consumption of alcohol.

References

  1. Patel S, Robinson R, Burk M (2002) "Hypertensive crisis associated with St. John's Wort." Am J Med, 112, p. 507-8

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.